SHANGHAI, Jan. 14, 2026 /PRNewswire/ -- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009, an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and A

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients Complex modalities are WuXi Biologics' core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs Bispecific/multispecific antibodies are WuXi Biologics' most exciting, fastest‑growing and highest‑margin engine.

- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this multi-virus treatment, 2026 may mark the inaugural year of modern treatments that can treat multiple viruses with one drug, perhaps even viruses that haven't hit us yet." SAN FRANCISCO, Jan. 14, 2026 /PRNewswi

As the holiday season comes to a close, one family reflects on a year of healing, gratitude, and renewed hope. SOMERSET, N.J., Jan. 14, 2026 /PRNewswire/ -- As families across New Jersey transition from the holidays into a new year, one family is reflecting on a medical crisis that unfolded during last year's holiday season—and the hope that followed. Just as holiday lights were going up last December, Jimmy, a 14-year-old student in Central New Jersey, thought he had a sinus infection. But days

ASX: CUV Frankfurt Börse: UR9 Level 1: CLVLY About About CLINUVEL People Corporate Governance Photomedicine Foundation Annual Reports Pharmaceuticals Pharmaceutical Development The Science Disease Entities Products PhotoCosmetics About PhotoCosmetics Polychromatic Photoprotection DNA Repair Melanogenesis Investors Investors Information ASX Announcements Analyst Coverage Media Coverage Company Snapshot Financial Summary Shareholder Information Investor Enquiry News Contact Store About CLINUVEL Pe

TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need population MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new standard of care as early as first relapse RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® (teclistamab-cqyv) monotherapy,

The FDA has become aware of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. Affected Product The FDA is aware that Vantive has issued a letter informing affected customers that Prismaflex Control Units have updated use instructions. Affected devices: Device Name Product Code UDI-DI Lot Numbers PRISMAFLEX ST100 SET US 107636US 00085412954073 All lots including and manufactured after 24G0072 PRIS

New therapeutic also could reduce scar tissue from injury SAN ANTONIO, Jan. 14, 2026 /PRNewswire/ -- A new grant could help reduce the amount of opioids needed to treat pain for burn patients by 90% and significantly decrease scar tissue from the wounds that restrict function. The $451,857 award from the Trauma Research and Combat Casualty Care Collaborative (TRC4), a University of Texas System initiative housed at UT Health San Antonio, could have major implications for two of the greatest clin

Lawsuit alleges anti-competitive conduct designed to suppress lawful compounding pharmaceuticals and limit patient choice GILBERT, Ariz., Jan. 14, 2026 /PRNewswire/ -- Strive Compounding Pharmacy, one of the nation's most celebrated providers of compounded medications, has filed a federal antitrust lawsuit against pharmaceutical giants Eli Lilly and Novo Nordisk, alleging a coordinated effort to suppress competition and limit patient access to lawful compounded GLP-1 medications. The lawsuit, f

Participation supports national effort to unlock cures for pediatric cancer using artificial intelligence. NASHVILLE, TN, UNITED STATES, January 14, 2026 / EINPresswire.com / -- Brim Analytics today announced its participation in the Advanced Research Projects Agency for Health (ARPA-H) Pediatric Cancer eXpansion (PCX), a national initiative designed to accelerate pediatric cancer research and care by expanding interoperable data-sharing infrastructure across the United States. PCX builds on inv